Boston Scientific BSX Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net sales of reportable segments by Business | |||||
| Cardiovascular | $13.29B+22.6% | $10.84B+22.8% | $8.83B+13.0% | $7.81B+16.2% | |
| MedSurg | $6.84B+13.4% | $6.03B+11.0% | $5.43B+10.6% | $4.91B+12.0% | |
| Net Sales by Product | |||||
| Cardiac Rhythm Management | $2.33B+2.4% | $2.28B+2.7% | $2.22B+5.7% | $2.1B+4.0% | |
| Electrophysiology | $3.33B+74.6% | $1.9B+138% | $800M+36.8% | $585M+60.7% | |
| Endoscopy | $2.92B+8.5% | $2.69B+8.2% | $2.48B+11.7% | $2.22B+3.8% | |
| Interventional Cardiology & Vascular Therapies | $4.64B+10.5% | $4.2B+10.8% | $3.79B— | —— | |
| Neuromodulation | $1.2B+8.6% | $1.11B+13.3% | $975M+6.3% | $917M+0.9% | |
| Urology | $2.71B+23.1% | $2.2B+12.0% | $1.96B+10.8% | $1.77B+12.0% | |
| Watchman | $1.96B+29.2% | $1.52B+18.9% | $1.28B+25.1% | $1.02B+22.9% | |
| Net Sales by Geography | |||||
| Asia-Pacific | $3.08B+14.7% | $2.69B+11.8% | $2.4B+13.5% | $2.12B+2.3% | |
| Europe, Middle East and Africa | $3.45B+6.9% | $3.23B+13.1% | $2.86B+13.0% | $2.53B+0.3% | |
| Latin America and Canada | $678M+8.5% | $625M+11.6% | $560M+19.7% | $468M+21.2% | |
| U.S. | $12.86B+26.0% | $10.21B+21.2% | $8.43B+10.4% | $7.63B+10.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Boston Scientific break its business down?
- Boston Scientific (BSX) reports net sales of reportable segments by business across 2 parts — Cardiovascular and MedSurg. Each is extracted from the segment footnotes and tracked over time.
- Where does Boston Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Boston Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
